axitinib,sunitinib,pembrolizumab
pfizer,merck
['sunitinib', 'axi+', 'key,note,42', 'pembro', 'rcc,(-irccs),(-srcc),(-urcc)', 'keynote-426', 'key,note,426']
5-year analysis of keynote-426 with axi+pembro vs sunitinib in 1l rcc shows ongoing superiority of vegf/tki combinations with updated pfs hr of 0.69 with improved orr and dor and os hr of 0.84 (adj for subsequent therapy, os hr 0.67). #asco23 
DAVA Oncology is a strategic consulting company that offers numerous products and services customized to fit biopharmaceutical drug development needs.